Legislators are asking 2 drug manufacturers to explain whether their recent extravagant hikes in medication prices reflect legitimate costs or are unjustified.
Sen Herb Kohl (D, Wis), chairman of the Senate Special Committee on Aging, and 3 Democratic House members sent letters on May 23 to the presidents and CEOs of Avanir Pharmaceuticals and URL Pharma Inc, asking for, among several requests, information regarding the costs of clinical trials that led to their drugs' approvals and how their drugs' initial prices were established (http://1.usa.gov/mmpnyZ).
Mitka M. Price Gouging? JAMA. 2011;306(2):145. doi:10.1001/jama.2011.925
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: